Meeting
2018 Genitourinary Cancers Symposium
Evaluating cell cycle progression score as a prognostic marker for non-muscle invasive bladder cancer (NMIBC).
Authors
Christopher J. Weight
University of Minnesota, Minneapolis, MN
Christopher J. Weight , Paari J Murugan , David Chesla , Resha Tejpaul , Ayman Soubra , William Boshoven , Zaina Sangale , Saradha Rajamani , Steven Stone , Brian R. Lane
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 476)
DOI
10.1200/JCO.2018.36.6_suppl.476
Abstract #
476
Poster Bd #
J5
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Association between CD47 expression and clinicopathologic characteristics and survival outcomes in MIBC.
First Author: Zin Myint
Poster
2022 ASCO Genitourinary Cancers Symposium
Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma.
First Author: Shruthi Naik
Poster
2022 ASCO Genitourinary Cancers Symposium
Identification of muscle-invasion status in bladder cancer patients using natural language processing and machine learning.
First Author: Ruixin Yang
Poster
2020 ASCO Virtual Scientific Program
Cell cycLe inhibitiON to target the EVolution of urOthelial cancer (CLONEVO): A single-arm, open-label window-of-opportunity trial of neoadjuvant abemaciclib in platinum-ineligible muscle invasive bladder cancer patients.
First Author: Jones Nauseef